Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LLY Stock Forecast 2025-2026
$1,025.28
Current Price
$923.78B
Market Cap
Buy 20
Hold 8
Sell 1
Wall St Analyst Ratings
Distance to LLY Price Targets
+46.3%
To High Target of $1,500.00
-3.2%
To Median Target of $992.50
-24.9%
To Low Target of $770.00
LLY Price Momentum
+10.9%
1 Week Change
+24.0%
1 Month Change
+37.4%
1 Year Change
+32.8%
Year-to-Date Change
-0.8%
From 52W High of $1,033.62
+64.4%
From 52W Low of $623.78
📊 TOP ANALYST CALLS
Did LLY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Eli Lilly is one of their latest high-conviction picks.
Latest LLY Stock Price Targets & Analyst Predictions
Based on our analysis of 41 Wall Street analysts, LLY has a bullish consensus with a median price target of $992.50 (ranging from $770.00 to $1,500.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $1,025.28, the median forecast implies a -3.2% downside. This outlook is supported by 20 Buy, 8 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Peter Verdult at Citigroup, projecting a 46.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LLY Analyst Ratings
20
Buy
8
Hold
1
Sell
LLY Price Target Range
Low
$770.00
Average
$992.50
High
$1,500.00
Current: $1,025.28
Latest LLY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LLY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $1,171.00 |
| Nov 12, 2025 | Citigroup | Peter Verdult | Buy | Maintains | $1,500.00 |
| Nov 10, 2025 | Freedom Capital Markets | Ilya Zubkov | Hold | Downgrade | $950.00 |
| Nov 10, 2025 | Leerink Partners | David Risinger | Outperform | Upgrade | $1,104.00 |
| Nov 7, 2025 | UBS | Trung Huynh | Buy | Maintains | $1,080.00 |
| Nov 6, 2025 | BMO Capital | Evan Seigerman | Outperform | Maintains | $1,100.00 |
| Oct 31, 2025 | Cantor Fitzgerald | Carter Gould | Overweight | Maintains | $985.00 |
| Oct 16, 2025 | Guggenheim | Seamus Fernandez | Buy | Reiterates | $948.00 |
| Oct 8, 2025 | Guggenheim | Seamus Fernandez | Buy | Maintains | $948.00 |
| Oct 3, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $1,023.00 |
| Sep 17, 2025 | Berenberg | Kerry Holford | Hold | Downgrade | $830.00 |
| Sep 16, 2025 | JP Morgan | Chris Schott | Overweight | Maintains | $1,050.00 |
| Aug 27, 2025 | HSBC | Rajesh Kumar | Hold | Upgrade | $700.00 |
| Aug 13, 2025 | Cantor Fitzgerald | Carter Gould | Overweight | Maintains | $825.00 |
| Aug 13, 2025 | Guggenheim | Seamus Fernandez | Buy | Maintains | $875.00 |
| Aug 11, 2025 | Deutsche Bank | James Shin | Buy | Maintains | $900.00 |
| Aug 8, 2025 | JP Morgan | Chris Schott | Overweight | Reiterates | $1,100.00 |
| Aug 8, 2025 | UBS | Trung Huynh | Buy | Maintains | $895.00 |
| Jul 11, 2025 | Guggenheim | Seamus Fernandez | Buy | Maintains | $942.00 |
| Jul 10, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $1,135.00 |
Eli Lilly and Company (LLY) Competitors
The following stocks are similar to Eli Lilly based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Eli Lilly and Company (LLY) Financial Data
Eli Lilly and Company has a market capitalization of $923.78B with a P/E ratio of 50.0x. The company generates $59.42B in trailing twelve-month revenue with a 31.0% profit margin.
Revenue growth is +53.9% quarter-over-quarter, while maintaining an operating margin of +48.3% and return on equity of +96.5%.
Valuation Metrics
Market Cap
$923.78B
Enterprise Value
$944.03B
P/E Ratio
50.0x
PEG Ratio
0.1x
Price/Sales
15.4x
Growth & Margins
Revenue Growth (YoY)
+53.9%
Gross Margin
+82.9%
Operating Margin
+48.3%
Net Margin
+31.0%
EPS Growth
+475.3%
Financial Health
Cash/Price Ratio
+1.1%
Current Ratio
1.5x
Debt/Equity
178.5x
ROE
+96.5%
ROA
+17.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Eli Lilly and Company (LLY) Business Model
About Eli Lilly and Company
What They Do
Develops and markets innovative pharmaceuticals.
Business Model
Eli Lilly generates revenue by developing prescription drugs and biopharmaceutical products across various therapeutic areas, including oncology, endocrinology, immunology, neuroscience, and rare diseases. The company's extensive research and development efforts, coupled with strategic collaborations, enable it to bring new treatments to market and improve patient outcomes, thus driving sales.
Additional Information
Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly has a significant global presence, operating in over 120 countries. The company's substantial market capitalization and listing on major exchanges highlight its scale and influence in the pharmaceutical and biotechnology sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
47,000
CEO
Mr. David A. Ricks
Country
United States
IPO Year
1972
Website
www.lilly.comEli Lilly and Company (LLY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
Nov 14, 2025
By Kinjel Shah
Analyst Blog
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
Nov 14, 2025
By Aparajita Dutta
ETF News and Commentary
Can Equities Stabilize after the Government Reopens?
As traders position for year-end, the government shutdown is over, major market indices are filling gaps, and seasonal momentum looms.
Nov 13, 2025
By Andrew Rocco
Investment Ideas
Latest News
Quick Summary
The drug giant is nearing a trillion-dollar valuation, continuing to outperform competitors despite significantly lowering prices on some medications.
Why It Matters
Lowering medication prices while outperforming rivals suggests strong market positioning and potential for increased sales, enhancing the company's valuation and attractiveness to investors.
Source: Market Watch
Market Sentiment:
Positive
Quick Summary
Eli Lilly & Co. (NYSE: LLY) stock rose over 635% from late 2020 to summer 2024 but has recently experienced a slowdown in growth.
Why It Matters
Eli Lilly's dramatic stock surge reflects strong market confidence and growth potential, impacting investor sentiment and future valuation assessments. A breather may indicate volatility ahead.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock
3 days ago
Quick Summary
Recursion Pharmaceuticals currently has the largest supercomputer in the pharma sector, but Eli Lilly is developing a potentially more powerful supercomputer.
Why It Matters
Eli Lilly's development of a more powerful supercomputer could enhance its drug discovery capabilities, potentially gaining a competitive edge over Recursion Pharmaceuticals and impacting market valuations.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Eli Lilly leads the market in weight-loss drugs, with government insurance coverage significantly benefiting the company.
Why It Matters
Eli Lilly's leadership in weight-loss drugs and government insurance coverage boosts its market position, potentially driving revenue growth and attracting more investors.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Eli Lilly reported positive mid-stage trial results for a weight management drug, positioning the company to lead the market through the end of the decade amid competition.
Why It Matters
Eli Lilly's promising trial results position it as a leader in the growing weight management market, potentially driving revenue growth and market share through the decade.
Source: The Motley Fool
Market Sentiment:
Positive
Cramer's Mad Dash: Eli Lilly
3 days ago
Quick Summary
Jim Cramer highlights Eli Lilly as a stock to watch closely, indicating potential interest for investors in the company's performance.
Why It Matters
Cramer's focus on Eli Lilly suggests potential growth or volatility, signaling investors to monitor the stock for strategic opportunities.
Source: CNBC Television
Market Sentiment:
Neutral
Frequently Asked Questions About LLY Stock
What is Eli Lilly and Company's (LLY) stock forecast for 2026?
Based on our analysis of 41 Wall Street analysts, Eli Lilly and Company (LLY) has a median price target of $992.50. The highest price target is $1,500.00 and the lowest is $770.00.
Is LLY stock a good investment in 2026?
According to current analyst ratings, LLY has 20 Buy ratings, 8 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1,025.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LLY stock?
Wall Street analysts predict LLY stock could reach $992.50 in the next 12 months. This represents a -3.2% decrease from the current price of $1,025.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Eli Lilly and Company's business model?
Eli Lilly generates revenue by developing prescription drugs and biopharmaceutical products across various therapeutic areas, including oncology, endocrinology, immunology, neuroscience, and rare diseases. The company's extensive research and development efforts, coupled with strategic collaborations, enable it to bring new treatments to market and improve patient outcomes, thus driving sales.
What is the highest forecasted price for LLY Eli Lilly and Company?
The highest price target for LLY is $1,500.00 from Peter Verdult at Citigroup, which represents a 46.3% increase from the current price of $1,025.28.
What is the lowest forecasted price for LLY Eli Lilly and Company?
The lowest price target for LLY is $770.00 from at , which represents a -24.9% decrease from the current price of $1,025.28.
What is the overall LLY consensus from analysts for Eli Lilly and Company?
The overall analyst consensus for LLY is bullish. Out of 41 Wall Street analysts, 20 rate it as Buy, 8 as Hold, and 1 as Sell, with a median price target of $992.50.
How accurate are LLY stock price projections?
Stock price projections, including those for Eli Lilly and Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 3:22 AM UTC